JP2023509402A5 - - Google Patents
Info
- Publication number
- JP2023509402A5 JP2023509402A5 JP2022539173A JP2022539173A JP2023509402A5 JP 2023509402 A5 JP2023509402 A5 JP 2023509402A5 JP 2022539173 A JP2022539173 A JP 2022539173A JP 2022539173 A JP2022539173 A JP 2022539173A JP 2023509402 A5 JP2023509402 A5 JP 2023509402A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019127902 | 2019-12-24 | ||
| CNPCT/CN2019/127902 | 2019-12-24 | ||
| PCT/CN2020/138580 WO2021129655A1 (en) | 2019-12-24 | 2020-12-23 | Novel anti-fgfr2b antibodies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023509402A JP2023509402A (ja) | 2023-03-08 |
| JP2023509402A5 true JP2023509402A5 (https=) | 2024-01-05 |
| JPWO2021129655A5 JPWO2021129655A5 (https=) | 2024-01-05 |
| JP7685999B2 JP7685999B2 (ja) | 2025-05-30 |
Family
ID=76573702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539173A Active JP7685999B2 (ja) | 2019-12-24 | 2020-12-23 | 新規抗ＦＧＦＲ２ｂ抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230055566A1 (https=) |
| EP (1) | EP4081546A4 (https=) |
| JP (1) | JP7685999B2 (https=) |
| KR (1) | KR20220119471A (https=) |
| CN (1) | CN114901692A (https=) |
| AR (1) | AR120883A1 (https=) |
| AU (1) | AU2020414910A1 (https=) |
| CA (1) | CA3160810A1 (https=) |
| MX (1) | MX2022007959A (https=) |
| TW (1) | TWI864207B (https=) |
| WO (1) | WO2021129655A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230052256A1 (en) * | 2019-12-24 | 2023-02-16 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| AU2021366691B2 (en) * | 2020-10-22 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-FGFR2 antibodies and methods of use thereof |
| AU2023243773A1 (en) * | 2022-03-28 | 2024-10-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Novel anti-fgfr2 antibodies. |
| KR20250099773A (ko) * | 2022-09-30 | 2025-07-02 | 3에이치 파머슈티컬즈 컴퍼니 리미티드 | 항-fgfr2b 항체 및 이의 용도 |
| AU2023416563A1 (en) * | 2022-12-28 | 2025-07-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-fgfr2b antibody and uses thereof |
| WO2024199362A1 (en) * | 2023-03-31 | 2024-10-03 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Novel anti-FGFR2 antibodies |
| WO2025067442A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京维立志博生物科技股份有限公司 | 抗fgfr2抗体和包含其的多特异性结合分子 |
| TW202540177A (zh) * | 2023-11-14 | 2025-10-16 | 大陸商蘇州創勝醫藥集團有限公司 | 抗－ＦＧＦＲ２ｂ免疫偶聯物及其於治療癌症的用途 |
| WO2025130860A1 (zh) * | 2023-12-18 | 2025-06-26 | 山东先声生物制药有限公司 | 抗FGFR2b抗体及其应用 |
| WO2025146131A1 (en) * | 2024-01-05 | 2025-07-10 | Beigene, Ltd. | ANTI-FGFR2b ANTIBODIES, CONJUGATES AND METHODS OF USE |
| CN120424212A (zh) * | 2024-01-26 | 2025-08-05 | 上海安领科生物医药有限公司 | 抗FGFR2b抗体及抗体药物偶联物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005037235A2 (en) | 2003-10-16 | 2005-04-28 | Imclone Systems Incorporated | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| AU2012351685A1 (en) | 2011-12-14 | 2014-07-03 | Seattle Genetics, Inc. | FGFR antibody drug conjugates (ADCs) and the use thereof |
| US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| PH12021552742A1 (en) * | 2013-08-01 | 2022-05-23 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| US20180291107A1 (en) * | 2015-11-24 | 2018-10-11 | Eli Lilly And Company | Combination therapy for cancer |
| WO2018095932A1 (en) | 2016-11-22 | 2018-05-31 | Merck Patent Gmbh | Monoclonal antibody directed to fgfr1 |
| WO2018129451A2 (en) * | 2017-01-09 | 2018-07-12 | Merrimack Pharmaceuticals, Inc. | Anti-fgfr antibodies and methods of use |
-
2020
- 2020-12-23 CA CA3160810A patent/CA3160810A1/en active Pending
- 2020-12-23 US US17/788,729 patent/US20230055566A1/en active Pending
- 2020-12-23 AR ARP200103628A patent/AR120883A1/es unknown
- 2020-12-23 CN CN202080089839.0A patent/CN114901692A/zh active Pending
- 2020-12-23 KR KR1020227025530A patent/KR20220119471A/ko active Pending
- 2020-12-23 EP EP20904511.1A patent/EP4081546A4/en active Pending
- 2020-12-23 WO PCT/CN2020/138580 patent/WO2021129655A1/en not_active Ceased
- 2020-12-23 MX MX2022007959A patent/MX2022007959A/es unknown
- 2020-12-23 AU AU2020414910A patent/AU2020414910A1/en active Pending
- 2020-12-23 JP JP2022539173A patent/JP7685999B2/ja active Active
- 2020-12-24 TW TW109145973A patent/TWI864207B/zh active